about
The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic reviewEffect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflictAntithrombotic therapy practices in US hospitals in an era of practice guidelinesConsensus and discordance in the management of growth hormone-treated patients: results of a knowledge, attitudes, beliefs, and practices survey.Reliability and validity of the brief insomnia questionnaire in the America insomnia surveyNighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS).Insomnia and the performance of US workers: results from the America insomnia survey.Improving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitus.Middle-of-the-night hypnotic use in a large national health planImpact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension.Days-out-of-role associated with insomnia and comorbid conditions in the America Insomnia Survey.Knowledge of binge eating disorder: a cross-sectional survey of physicians in the United States.National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes.Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis.A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.Ongoing issues in pneumonia care: when to admit, how to treat and the role of oral therapyChanging Patients' Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial
P50
Q26749996-E8DA38CD-F19E-432F-B965-ACA9F706D789Q27306966-B108DA4F-5A32-4312-B979-115A708FDABFQ28183433-536C8481-A9BC-4E69-80FC-36F3404BE938Q34189815-5EDA3E70-6488-455C-9A55-33AE4E1ECB4FQ34197690-7F87B6F3-CDA8-4AE7-9E9C-C6BB3F576E95Q35110621-D87F3B84-BE5D-4F71-B14A-54A77E2DA330Q35169400-E509BCE6-0D2D-461F-B22D-E73C94F137EBQ35586553-67160FCB-3252-4C0B-8922-D27E11E811EEQ36898778-480787B9-FD79-4FF5-8B78-90FE5664E6BBQ39185838-77B818FD-EF20-4E55-8177-270B10093502Q44138534-F636B095-B9D5-4D3E-BD16-FB0816C03394Q44668372-5E552BDA-C892-4F3C-B100-93876B2C27D9Q48280801-C8655A2E-ED0E-4216-BA4D-DF98A33571C8Q50540946-0542804A-02BC-4410-BB92-9837B3DF9133Q50600997-7712740D-C922-416A-84E5-20D9A8DE6B9AQ53115425-DEA64BD1-3C82-4823-85C7-48911D2718C5Q53668916-5857D014-043E-4CFE-BE88-A8E908985D18Q73261808-20FECB64-A456-4DF7-99A9-0B4723F3D03DQ88047744-6803A6A3-258E-4D4E-A80D-FA786AED554A
P50
description
researcher
@en
wetenschapper
@nl
name
A C Shillington
@en
A C Shillington
@nl
type
label
A C Shillington
@en
A C Shillington
@nl
prefLabel
A C Shillington
@en
A C Shillington
@nl
P106
P31
P496
0000-0003-2534-0960